Our work implies that TKTL1 may be a promising prognostic biomarker for KIRC patients that respond to anti-PD-1 therapy, providing insight into the possible role of TKTL1 in tumor immunology and its application as a prognostic biomarker and novel therapeutic target for kidney cancer. The gene discussed is TKTL1; the disease is neoplasm.